Results 151 to 160 of about 101,745 (215)

Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.
Roxane Dilcher, Charles B. Malpas, Stuart J. McDonald, William T. O’Brien, Craig Despott, Kelly L. Bertram, Matthew P. Pase, Lukas Frontzkowski, Meng Law, Terence J. O’Brien, Lucy Vivash   +10 more
wiley   +1 more source

SAGE (safer analgesia): a protocol for a pragmatic cluster randomised controlled trial to reduce the use of high-risk medicines in people with chronic back and/or neck pain. [PDF]

BMJ Open
Abdel Shaheed C, McLachlan AJ, Mathieson S, Ivers R, Clare PJ, Blyth F, Stanaway F, Degenhardt L, Gnjidic D, French S, Thompson R, Hilmer S, Pinheiro M, Machado GC, Austin T, Gardner T, Sharma S, Bennett A, Boogs M, McMaugh J, Vizza L, Downie A, Tracy M, Hopkins R, Osman R, Lindley RI, Hayes C, McCaffery K, Maher C.   +28 more
europepmc   +1 more source

Functional and Structural Evidence of Neurofluid Circuit Aberrations in Huntington Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Disrupted neurofluid regulation may contribute to neurodegeneration in Huntington disease (HD). Because neurofluid pathways influence waste clearance, inflammation, and the distribution of central nervous system (CNS)–delivered therapeutics, understanding their dysfunction is increasingly important as targeted treatments emerge.
Kilian Hett, Abigail Dubois, Melanie Leguizamon, Alexander Song, Paula Trujillo, Colin D. McKnight, Ciaran M. Considine, Manus J. Donahue, Daniel O. Claassen   +8 more
wiley   +1 more source

Post-market surveillance of antiretroviral drug quality in Tanzania in the context of rising HIV drug resistance. [PDF]

Sci Rep
Mlugu EM, Mhagama JB, Sangeda RZ, Kunambi PP, Samwel T, Shiletiwa N, Gotora G, Chambiri SM, Matiko D, Hipolite D, Mwalwisi YH, Fimbo AM.   +11 more
europepmc   +1 more source

Vestibular Patient Journey: Insights From Vestibular Disorders Association (VeDA) Registry

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Vestibular symptoms impose a high burden of disability. Understanding real‐world diagnostic and treatment pathways can identify care gaps and guide interventions. We aimed to characterize symptom profiles, diagnostic trends, provider involvement, and treatment patterns in vestibular disorders.
Ali Rafati, Sami I. Nassar, Shaun A. Nguyen, Patricia L. Gerend, Michael C. Schubert, Michael T. Teixido, Frederick A. Godley, Joel A. Goebel, Cynthia A. Ryan, Habib G. Rizk, Amir Kheradmand   +10 more
wiley   +1 more source

Redispensing oral anticancer drugs in Denmark (DANROAD): a national, multicentre, prospective implementation study protocol. [PDF]

BMJ Open
Petersen AST, Moriat KB, Bekker C, Carlsen HH, Christensen MMH, Dunvald AD, Ennis ZN, Gram EB, Henriksen DP, Johansen KB, Lund ML, Nielsen ML, Obling ML, Overgaard LK, Strudwick C, Vestergaard H, Pedersen SA.   +16 more
europepmc   +1 more source

Baseline Regional Cholinergic Denervation Predicts Cognitive Trajectories in Moderate Parkinson Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cognitive decline is a disabling and variable feature of Parkinson disease (PD). While cholinergic system degeneration is linked to cognitive impairments in PD, most prior research reported cross‐sectional associations. We aimed to fill this gap by investigating whether baseline regional cerebral vesicular acetylcholine transporter ...
Taylor Brown, Giulia Carli, Prabesh Kanel, Stiven Roytman, Jaimie Barr, Nicolaas I. Bohnen, Roger L. Albin   +6 more
wiley   +1 more source

Transitioning regulatory authorities in South Africa: a comparative review of the organisational structure and management practices. [PDF]

J Pharm Policy Pract
Hattingh A, Joubert J, Viljoen M.
europepmc   +1 more source

A Prospective Study of Individuals at Risk of Multiple Sclerosis Informs the Design of Primary Prevention Studies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective In multiple sclerosis, the optimal time for deploying a therapeutic intervention is before the central nervous system is damaged; given the success of trials treating the earliest stage of MS, the radiologically isolated syndrome, developing primary prevention strategies is an important next challenge.
Amy W. Laitinen, Ceren Tozlu, Tina Roostaei, Fatoumata Diallo, Kaho Onomichi, Jiyeon Son, Zongqi Xia, Philip L. De Jager   +7 more
wiley   +1 more source

A HEARTS-based integrated model for noncommunicable disease control in primary health care in Peru. [PDF]

Lancet Reg Health Am
Herrera-Añazco P, Diaz-Arocutipa C, Alcántara PK, Benites-Zapata V.   +3 more
europepmc   +1 more source